María Luz Martín-Martín

This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: Janssen Pharmaceutica Nv, Vanderbilt University. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: María Luz Martín-Martín. Retrieved from https://idiyas.com/inventor/maria-luz-martin-martin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 75.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Salamanca, ES (2014)
Toledo, ES (2014 - 2020)

Company Filing History:

7 out of 2,103

Janssen Pharmaceutica Nv

patents

1 out of 1,226

Vanderbilt University

patents

Years Active: 2014-2020

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10668065 - 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2020-06-02),

2. 10519162 - 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-12-31),

3. 10220032 - 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-03-05),

4. 10017514 - [object Object] (2018-07-10),

5. 10005785 - Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors (2018-06-26),

6. 8865725 - Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors (2014-10-21),

7. 8859543 - Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases (2014-10-14),

8. 8716282 - Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors (2014-05-06),

Title: Inventor Spotlight: María Luz Martín-Martín

Introduction

María Luz Martín-Martín is an accomplished inventor hailing from Toledo, Spain. With a total of four patents to his name, he is recognized for his significant contributions to the field of pharmaceutical innovation. His work focuses on developing compounds that could play a critical role in medical treatments.

Latest Patents

His latest patents include groundbreaking inventions involving 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds, which have been identified as negative allosteric modulators of metabotropic glutamate receptor subtype 2 (mGluR2). The inventions not only relate to these novel compounds but also encompass pharmaceutical compositions containing them, methods for preparing these derivatives, and their potential applications in preventing or treating disorders associated with the mGluR2 receptor.

Career Highlights

María Luz is currently affiliated with Janssen Pharmaceutica NV, where he continues to push the boundaries of pharmaceutical research. His role involves collaborating with fellow researchers to develop innovative solutions that meet pressing medical needs.

Collaborations

Throughout his career, María Luz has worked alongside notable colleagues, including Susana Conde-Ceide and Michiel Luc Maria Van Gool. These collaborations have contributed to his success and the advancement of new therapeutic strategies in the pharmaceutical industry.

Conclusion

María Luz Martín-Martín exemplifies the spirit of innovation within the realm of pharmaceuticals. With his impressive patent portfolio and ongoing collaborations, he stands at the forefront of developing new treatments that may significantly enhance patient care. As his work continues to evolve, the impact of his inventions will likely resonate throughout the medical community and beyond.

Profile summary based on public USPTO records.